2020 IDSA Guidance for Treatment of Antimicrobial-Resistant Gram-Negative Infections Deprioritizes Polymyxin Use

Video

Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections.

In an interview with Pharmacy Times, Thomas Lodise, PharmD, PhD, discussed new guidance released by the Infectious Diseases Society of America (IDSA) on the treatment of antimicrobial resistant gram-negative infections. The guidelines were reviewed in a session at the American Society of Health-System Pharmacists titled "Beyond the Top Line: A Point-Counterpoint Discussion of the 2020 Antimicrobial Resistant Gram-Negative Infection Treatment Guideline."

Lodise said that one of the notable takeaways is the de-prioritization of polymyxins for the treatment of these infections. He also discussed key points from the guidance, current regimen recommendations, and clinical scenarios where therapy recommendations outside of the guidelines might be considered.

Related Videos
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room - Image credit: pressmaster | stock.adobe.com
pain management palliative care/Image Credits: © Aleksej - stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
3d rendered illustration of lung cancer 3D illustration - Image credit:  appledesign | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.